|
山東新華制藥股份有限公司 - H股, 00719.HK - 綜合損益表 |
2022-12 |
2021-12 |
2020-12 |
2019-12 |
2018-12 |
2017-12 |
2016-12 |
2015-12 |
2014-12 |
2013-12 |
2012-12 |
2011-12 |
2010-12 |
2009-12 |
2008-12 |
2007-12 |
2006-12 |
2005-12 |
營業額 |
7,502,987 |
6,560,078 |
6,005,587 |
5,606,021 |
5,244,644 |
4,515,717 |
4,014,963 |
3,597,033 |
3,533,178 |
3,338,512 |
2,932,116 |
2,917,860 |
2,589,447 |
2,295,101 |
2,077,753 |
1,865,568 |
1,685,367 |
1,712,102 |
經營溢利 |
476,707 |
425,591 |
422,485 |
387,436 |
344,574 |
281,681 |
147,167 |
92,068 |
90,589 |
63,246 |
24,721 |
82,026 |
123,707 |
106,548 |
31,924 |
41,733 |
30,432 |
15,926 |
非經營/ 特殊項目 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
4,928 |
7,639 |
0 |
0 |
0 |
聯營公司 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
3,202 |
5,141 |
5,260 |
4,912 |
1,884 |
-4,369 |
-699 |
-2,732 |
除稅前經營溢利 |
471,774 |
421,233 |
411,638 |
381,393 |
332,328 |
268,174 |
159,968 |
117,730 |
90,589 |
63,246 |
33,515 |
91,272 |
128,967 |
116,388 |
41,447 |
37,364 |
29,733 |
13,194 |
稅項 |
45,460 |
59,159 |
64,525 |
58,277 |
51,901 |
46,925 |
26,921 |
23,721 |
23,016 |
14,270 |
8,499 |
13,302 |
22,159 |
13,008 |
5,677 |
-400 |
7,784 |
13,696 |
少數股東權益 |
15,121 |
13,526 |
22,254 |
23,149 |
25,112 |
11,657 |
10,776 |
10,946 |
17,609 |
10,838 |
2,599 |
3,595 |
5,509 |
3,693 |
5,706 |
5,946 |
-812 |
-1,731 |
股東應占溢利 |
411,194 |
348,548 |
324,860 |
299,966 |
255,314 |
209,592 |
122,272 |
83,062 |
49,964 |
38,138 |
22,417 |
74,375 |
101,299 |
99,687 |
30,064 |
31,818 |
22,761 |
1,229 |
貨幣 |
人民幣 |
人民幣 |
人民幣 |
人民幣 |
人民幣 |
人民幣 |
人民幣 |
人民幣 |
人民幣 |
人民幣 |
人民幣 |
人民幣 |
人民幣 |
人民幣 |
人民幣 |
人民幣 |
人民幣 |
人民幣 |
單位 |
千 |
千 |
千 |
千 |
千 |
千 |
千 |
主要項目 |
折舊 |
489,403 |
438,580 |
385,390 |
51,134 |
302,333 |
283,464 |
255,848 |
228,076 |
193,890 |
184,066 |
161,294 |
134,727 |
120,285 |
115,921 |
115,739 |
103,710 |
99,661 |
94,816 |
利息 |
49,707 |
53,103 |
59,759 |
55,318 |
54,552 |
52,750 |
63,661 |
67,591 |
78,370 |
73,592 |
60,420 |
27,919 |
17,598 |
19,308 |
17,956 |
12,183 |
20,475 |
22,406 |
利息撥作發展資本 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
3,553 |
3,965 |
2,818 |
0 |
0 |
0 |
0 |
0 |
0 |
240 |
處置/重估固定資產 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
稅率(%) |
9.64 |
14.04 |
15.68 |
15.28 |
15.62 |
17.5 |
16.83 |
20.15 |
25.41 |
22.56 |
25.36 |
14.57 |
17.18 |
11.18 |
13.7 |
|
26.18 |
103.8 |
營業額增長(%) |
14.37 |
9.23 |
7.13 |
6.89 |
16.14 |
12.47 |
11.62 |
1.81 |
5.83 |
13.86 |
0.49 |
12.68 |
12.82 |
10.46 |
11.37 |
10.69 |
-1.56 |
12.31 |
股東應占溢利增長(%) |
17.97 |
7.29 |
8.3 |
17.49 |
21.82 |
71.42 |
47.2 |
66.24 |
31.01 |
70.13 |
-69.86 |
-26.58 |
1.62 |
231.58 |
-5.51 |
39.79 |
1750.0 |
|
核數師意見 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
說明:1代表無保留意見;2代表保留意見;3代表修改意見
|
|